Rockwell Medical, Inc. to Present at 31st Annual Piper Jaffray Healthcare Conference
November 21 2019 - 6:50AM
Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the
"Company") today announced that Stuart Paul, Chief Executive
Officer, will present at the 31st Annual Piper Jaffray Healthcare
Conference as follows:
Date: |
Tuesday,
December 3, 2019 |
Time: |
12:00 p.m. Eastern Standard Time |
Location: |
Lotte New York Palace, New York, NY |
Webcast: |
https://event.webcasts.com/starthere.jsp?ei=1273475&tp_key=a58ce392ac |
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.rockwellmed.com, under the “Investors” section.
About Rockwell Medical Rockwell Medical is a
biopharmaceutical company dedicated to transforming anemia
management in a wide variety of therapeutic areas and across the
globe, improving the lives of very sick patients. The Company’s
initial focus is the treatment of anemia in end-stage renal disease
(ESRD). Rockwell Medical's exclusive renal drug therapy, Triferic,
is the only FDA-approved therapeutic indicated for iron replacement
and maintenance of hemoglobin in hemodialysis patients. The Company
has developed multiple formulations of Triferic (1) FDA-approved
Dialysate Triferic, and (2) I.V. Triferic, for which the Company
filed a New Drug Application in May 2019. Rockwell Medical is also
an established manufacturer, supplier and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis
providers and distributors in the U.S. and abroad. Please visit
www.rockwellmed.com for more information.
About Triferic Triferic is the only
FDA-approved therapy in the U.S. indicated to replace iron and
maintain hemoglobin in hemodialysis patients via dialysate during
each dialysis treatment. Triferic has a unique and differentiated
mechanism of action which has the potential to provide significant
benefits to patients and health care economics. Triferic represents
one of the most innovative medical advancements in patient iron
management in the past few decades – with the potential to be the
future standard of care.
Triferic delivers approximately 5-7 mg iron with every
hemodialysis treatment to the bone marrow and maintains hemoglobin
without increasing iron stores (ferritin). Unlike traditional IV
iron products, Triferic donates iron immediately and completely to
transferrin (carrier of iron in the body) upon entry into the blood
and is then transported directly to the bone marrow to be
incorporated into hemoglobin, with no increase in ferritin (stored
iron and inflammation) and no reports of anaphylaxis in over
1,000,000 patient administrations, addressing a significant medical
need in overcoming Functional Iron Deficiency (FID) in ESRD
patients. Please visit www.triferic.com to view the Triferic
mechanism-of-action (MOA) video and for more information.
Important Safety InformationSerious
hypersensitivity reactions, including anaphylactic-type reactions,
some of which have been life-threatening and fatal, have been
reported in patients receiving parenteral iron products. Patients
may present with shock, clinically significant hypotension, loss of
consciousness, and/or collapse. Monitor patients for signs and
symptoms of hypersensitivity during and after hemodialysis until
clinically stable. Personnel and therapies should be immediately
available for the treatment of serious hypersensitivity reactions.
Hypersensitivity reactions have been reported in 1 (0.3%) of 292
patients receiving Triferic in two randomized clinical trials.
Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and
transferrin saturation.
The most common adverse reactions (≥3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural
hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in
extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back
pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula
thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).
For more information, including full prescribing information,
visit: http://www.triferic.com.
Forward-Looking Statements Certain statements
in this press release may constitute "forward-looking statements"
within the meaning of the federal securities laws, including, but
not limited to, Rockwell Medical’s intention to bring to market
Triferic, and I.V. Triferic. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "could," "plan," "potential," "predict," "forecast,"
"project," "intend" or similar expressions, or statements regarding
intent, belief, or current expectations, are forward-looking
statements. While Rockwell Medical believes these forward-looking
statements are reasonable, undue reliance should not be placed on
any such forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical's SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include: statements about the issuance of a unique J code for our
Triferic Powder Packet; timing and regulatory approval process for
Dialysate Triferic in China; the potential market opportunity and
commercialization of Dialysate Triferic in China upon regulatory
approval; timing and regulatory approval process of our NDA filing
for I.V. Triferic as filed with the FDA; potential market
opportunity for I.V. Triferic, as well as other Rockwell Medical
products; the pricing and reimbursement status for I.V. Triferic
under CMS’ final rule relating to TDAPA as announced by CMS on
October 31, 2019; liquidity and capital resources; expected
duration of Rockwell Medical’s existing working capital; the
success of our commercialization of Dialysate Triferic, which
commenced in May 2019; and timing and success of our efforts to
maintain, grow and improve the profit margin of the Company’s
concentrate business. Rockwell Medical expressly disclaims any
obligation to update or alter any statements whether as a result of
new information, future events or otherwise, except as required by
law.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Contact Investor Relations: Lisa M. Wilson,
In-Site Communications, Inc. T: 212-452-2793 E:
lwilson@insitecony.com
Source: Rockwell Medical, Inc.
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024